Prev: A flawed paradigm
Next: Effect of baclofen on esophagogastric motility and gastroesophageal reflux
From: trigonometry1972 on 13 Sep 2007 07:19
Gastroenterol. 2006 Jun;41(6):513-23.

Therapeutic strategies for functional dyspepsia and the introduction
of the Rome
III classification.

Suzuki H, Nishizawa T, Hibi T.

Department of Internal Medicine, Keio University School of Medicine,
35
Shinanomachi, Tokyo, 160-8582, Japan.

Although placebo response rates in clinical trials for functional
dyspepsia (FD)
are more than 30%, a recent meta-analysis based on randomized
controlled trials (RCTs) showed that antisecretory drugs were more or
less superior to placebos. On the other hand, large-scale RCTs on the
efficacy of treatment with prokinetics on FD are still needed.
Indications for antibiotic eradication therapy for Helicobacter pylori-
positive FD are still controversial, but there seems to be a small but
significant therapeutic gain achieved with H. pylori eradication.
Since preprandial and postprandial symptomatic disturbances are very
important targets for FD treatment, ghrelin, a novel appetite-
promoting gastrointestinal peptide that also promotes gastric motility
or basal acid secretion can be expected to be a therapeutic target. In
the recently published Rome III classification, FD is redefined for
patients with symptoms thought to originate from the gastroduodenal
region, specifically epigastric pain or burning, postprandial
fullness, or early satiation, and it is divided into the subcategories
postprandial distress syndrome and epigastric pain syndrome. These new
criteria are of value in clinical practice, for epidemiological,
pathophysiological, and clinical research, and for the development of
new therapeutic strategies.

PMID: 16868798

------------------------------------

Likely our "friends" in the drug industry will develop
as toxic agonist to ghrelin. But perhaps some company
may develop recombinant form of the peptide to
be administered thru the lungs or by injection?

 | 
Pages: 1
Prev: A flawed paradigm
Next: Effect of baclofen on esophagogastric motility and gastroesophageal reflux